HPV NYC

In 2006, an HPV vaccine (Gardasil) was approved by the FDA. It is currently recommended for both males and females aged 9 to 26 years. This vaccine has been shown to be safe and highly effective in preventing infection with the four most common HPV types (6, 11, 16, and 18) in women who have had no previous exposure to the virus. However, it is less effective in those who have already been infected with HPV, and it does not protect against all types of HPV infection. Studies are underway to determine whether the vaccine is safe and effective in older women and in males.
Gardasil 9 has activity against the four viral types in the basic Gardasil, but also against virus types 31, 33, 45, 52, and 58 (for a total of 9 viral types, hence the name).
Another vaccine against HPV types 16 and 18, Cervarix, was been approved by the FDA for females aged 10 to 25 years, but was withdrawn from the US market in 2016.
Because no treatment is 100% effective, it is important to prevent the spread of HPV, which causes genital warts and some cancers whenever possible. Transmission of genital warts can be decreased ifcondoms are used and the infected individual refrains from sexual activity until therapy is completed.